




















Tumor suppressor genes and their role in cancer 




























The main aims of this bibliographic review are to: 
• Introduce the hallmarks of cancer, the capabilities that enable normal cells to transform to cancerous cells 
• Briefly describe the history of the identification of tumor suppressor genes  (TSGs) 
• Review and synthesize the principal tumor suppressor pathways, their involvement in cancer pathogenesis and the consequences of their inactivation or loss of function  
• Introduce the genetic and epigenetic modifications associated with TSGs 
• Briefly compare the information available in human and veterinary medicine regarding TSGs 
Objectives 
 
• Suppressors of cell cycle proliferation  
• Recessive autosomic inheritance   
• The inheritance of a single mutant allele increases susceptibility to caner  
• Related to familial cancers or inherited predisposition to cancer 
• The same gene is frequently inactivated in sporadic cancers 
 
Tumor suppressor genes 
 
1. Sustaining proliferative signalling  
2. Insensitivity to anti-growth signals  
3. Evading apoptosis 
4. Replicative immortality  
5. Inducing angiogenesis  
6. Tissue invasion and metastasis 












• Mutations  
• Loss of heterozygosity  
• DNA Methylation  
• miRNAs  
Inactivation of TSG 
Genetic  
Epigenetic  
• First TSG described in inherited 
retinoblastoma  
• RB irreversibly blocks cell cycle progression 
(G1/S phase) 
• Mutated in many cancers: breast cancer, 
small cell lung cancer and bladder cancer 
p53: the guardian of the genome  
New diagnostic and 
therapeutic strategies  
 
•  The identification of RB and TP53 helped to establish the basis for further 
studies about TSG and their characteristics as cancer-associated genes 
•  TSGs are key regulators of cell cycle progression 
• The main properties of TSGs may be resumed as: having a recessive 
autosomic inheritance, act as suppressors of cell cycle progression and being 
related to familial and sporadic cancers or inherited predisposition to cancer 
• TP53 is the most frequently mutated TSG in cancer because of its involvement 
in many tumor suppressor mechanisms 
• TSGs are silenced by genetic and epigenetic modifications, which hold 
promise for developing new therapeutic and diagnostic strategies. 
• TSGs may be suitable targets for anticancer therapies that proved to be 
effective both in vitro and in vivo although further research is needed.   












• Suppressor of cell proliferation  
• Negative regulator of the PI3K/AKT 
cascade 
• Mutated in numerous cancers: central 
nervous system, skin and prostate 
cancers.  
•  Germ line mutations are associated 
with Cowden’s disease  
 
 
•  TP53 is the most frequently mutated TSG in cancer (40 – 50%) 
•  Missense mutations (~74%) within the central binding domain 
•  Mutant p53 inhibits wild type p53 preventing genome protection  
•  Inhibition of mutant p53 as an effective therapy for malignant phenotypes? 





p53 mutations  
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•  TSGs and tumor suppressor pathways are highly conserved in mammals 
•  Alterations in RB, TP53 or PTEN are present in many animal and human cancers 
•  Pets are suitable animal models for human diseases such as cancer 
•  The lack of standards of care for pets provides an opportunity for 
experimental therapies that benefit both animal and human cancer patients 
Human and veterinary medicine  
Mitotic 
signals 







Cell cycle progression: 
         Inhibitors  
         Promoters  
Cell cycle progression: 
         Inhibitors  
         Promoters  
Cell cycle 
inhibition 
PTEN 
PIP3 
Akt/PKB 
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